Show simple item record

dc.creatorIgnjatović, Nenad
dc.creatorNinkov, Petar
dc.creatorSabetrasekh, Roya
dc.creatorLyngstadaas, Staale Petter
dc.creatorUskoković, Dragan
dc.date.accessioned2019-02-21T13:25:11Z
dc.date.available2019-02-21T13:25:11Z
dc.date.issued2009
dc.identifier.isbn978-86-80321-18-9
dc.identifier.urihttp://dais.sanu.ac.rs/123456789/4932
dc.description.abstractCalcium-phosphate/poly(dl-lactide-co-glycolide) (CP/PLGA) composite biomaterial in granular form showed a high potential in the reconstruction of bone tissue. Compared to pure polymers, the combination of CP with biodegradable polymers used in bone drug delivery systems shows certain advantages. Composite biomaterials in nano particulate (NPs) form may have significant advantages over those in micro- or submicro-particulate form. The purpose of the study presented in this paper has been to examine the possibility of the synthesis of a new nanoparticulate system for controlled and systemic drug delivery with double effect. In the first step, a drug is released from bioresorbable polymer; in the second stage, after resorption of the polymer, non-bioresorbable calcium phosphate remains the chief part of the particle and takes the role of a filler, filling a bone defect. The obtained tigecycline-loaded calcium-phosphate(CP)/poly(dl-lactide-co-glycolide)(PLGA) nano particles contain calcium phosphate coated with bioresorbable polymer and 0.6, 2 and 5wt% tigecycline. The composite was analyzed by FT-IR, XRD, HPLC and AFM methods. The average particle size of the nanocomposite increases with the augmentation of the part of antibiotics, and it ranges from 65 to 95 nm. Release profiles of tigecycline were obtained by UV-VIS spectroscopy in physiological solution at 37oC. Experimental results were analyzed using Peppas and Weibull mathematical models. Based on kinetic parameters, tigecycline release was defined as non-Fickian transport. The in vitro cytotoxicity of the nanocomposite was examined on standard cell lines of MC3T3-E1, in vitro. The obtained low values of LDH activity (under 37%) indicate low cytotoxicity level. Inhibition of bacteria in aerobic and anaerobic conditions in vitro was analyzed after 1, 2 and 3 weeks. The behaviour of the composite under real-life conditions was analyzed through implantation of the nanocomposite into living organisms, in vivo. The system with the lowest tigecycline content proved to be an adequate system for local and controlled release.sr
dc.language.isoensr
dc.publisherBelgrade : Institute of Technical Sciences of SASAsr
dc.relationinfo:eu-repo/grantAgreement/MESTD/MPN2006-2010/142006/RS//sr
dc.rightsopenAccesssr
dc.sourceProgramme and The Book of Abstracts / Eleventh Annual Conference YUCOMAT 2009, Herceg Novi, August 31 – September 4, 2009sr
dc.subjectCalcium-phosphate/poly(dl-lactide-co-glycolide)sr
dc.subjectCP/PLGAsr
dc.subjectcomposite biomaterialssr
dc.subjectbone tissue reconstructionsr
dc.titleIn vitro and in vivo performance of nanosized hydroxyapatite particles coated with poly-dl-lactide-co-glycolide as systems for drug delivery of tigecyclinesr
dc.typeconferenceObjectsr
dc.rights.licenseBY-NC-NDsr
dcterms.abstractИгњатовић, Ненад; Сабетрасекх, Роyа; Лyнгстадаас, Стаале Петтер; Ускоковић, Драган; Нинков, Петар;
dc.citation.spage71
dc.citation.epage71
dc.type.versionpublishedVersionsr
dc.identifier.fulltexthttp://dais.sanu.ac.rs/bitstream/id/15431/Ignjatovic_YUCOMAT 2009_71.pdf


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record